Skip to main content
Nexalin Technology, Inc. logo

Nexalin Technology, Inc. — Investor Relations & Filings

Ticker · NXL ISIN · US65345B2016 US Manufacturing
Open in API
Filings indexed 177 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country US United States of America
Listing US NXL

About Nexalin Technology, Inc.

https://nexalin.com

Nexalin Technology, Inc. is a medical technology company that develops non-invasive neurostimulation devices for mental and neurological health conditions. Its core technology utilizes a patented, frequency-based waveform designed to interact with deep brain structures to modulate neurochemicals, offering a drug-free treatment alternative. The company's devices are FDA-cleared for the treatment of anxiety, insomnia, and depression. Nexalin is advancing its technology through clinical trials for expanded applications, including treatment-resistant depression, Alzheimer's disease, and substance use disorders. It is also developing next-generation systems, such as the Gen-2 and HALO devices, with a focus on enhanced therapeutic benefits and potential at-home use.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 92% confidence The document is an SEC Form 8-K “Current Report” filed under the Securities Exchange Act of 1934, disclosing entry into material agreements and unregistered equity sales. It is not an annual or quarterly report, earnings release, proxy, or investor presentation; nor is it an officer certification or simple announcement of a forthcoming report. As a formal regulatory filing, it falls under the Regulatory Filings category (RNS).
2026-05-19 English
10-Q - Nexalin Technology, Inc. (0001527352) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-08 English
8-K - Nexalin Technology, Inc. (0001527352) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes details about entering into a material definitive agreement (a Scope of Work with a clinical research organization), a press release about a clinical trial advancement, and references to exhibits including a press release. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a transcript, proxy, or governance report. It is a regulatory filing announcing a material event, consistent with the purpose of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 5268 characters, which is not extremely short, but the content is clearly an announcement/reporting of a material event rather than a full report itself.
2026-04-22 English
10-K - Nexalin Technology, Inc. (0001527352) (Filer)
Annual Report FY 2025
2026-03-25 English
8-K - NEXALIN TECHNOLOGY, INC. (0001527352) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or disclosures by a company. The text includes a press release about a clinical trial advancement and regulatory strategy, but does not contain financial statements or detailed financial data. It is not an earnings release or annual/interim report. The document is a regulatory announcement of a material event, typical of Form 8-K filings. Therefore, it fits best under Regulatory Filings (RNS). The document length is 5696 characters, which is relatively short and consistent with a regulatory announcement rather than a full report.
2026-02-25 English
8-K Filing
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 21, 2026, by Nexalin Technology, Inc. It reports receipt of a deficiency letter from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing. The document details the compliance period and potential delisting consequences. It is a regulatory announcement about the company's listing status, specifically a notice related to potential delisting due to failure to meet Nasdaq's minimum bid price rule. The content matches the definition of a Delisting Announcement (DLST). The document length is 6540 characters, which is sufficient to contain substantive information rather than just a brief announcement or reference to another report. Therefore, the correct classification is DLST with high confidence.
2026-01-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.